Hunting for a cure: The therapeutic potential of gene therapy in Duchenne muscular dystrophy

被引:3
作者
Hashim, Hasnur Zaman [1 ]
Abdullah, Shahrin Tarmizi Che [1 ]
Sulaiman, Wan Aliaa Wan [2 ]
Hoo, Fan Kee [2 ]
Basri, Hamidon [2 ]
机构
[1] Int Islamic Univ Malaysia, Dept Internal Med, Pahang, Malaysia
[2] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Neurol Unit, Serdang 43400, Selangor, Malaysia
来源
TZU CHI MEDICAL JOURNAL | 2014年 / 26卷 / 01期
关键词
Cure; Duchenne; Gene therapy; Muscular dystrophy;
D O I
10.1016/j.tcmj.2014.02.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Duchenne muscular dystrophy (DMD) is an incurable disease and the search for a cure is a challenging journey. However, with recent encouraging progress, we are seeing a light at the end of a long tunnel. This review focuses on several main strategies in gene therapy, including truncated dystrophin gene transfer via viral vectors, antisense mediated exon skipping to restore the reading frame, and readthrough of translation stop codons. An exon skipping agent, eteplirsen, and a termination codon read drug, ataluren, are currently the most promising therapies. With better understanding of the molecular mechanism, gene therapy has improved with regard to the key areas of gene stability, safety, and route of delivery. Consequently, it has emerged as an exciting and hopeful means for novel treatment of this devastating disease. Copyright (C) 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
引用
收藏
页码:5 / 9
页数:5
相关论文
共 50 条
  • [31] Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy
    A Ferrer
    K E Wells
    D J Wells
    Gene Therapy, 2000, 7 : 1439 - 1446
  • [32] Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy
    Moriyama, Hidenori
    Yokota, Toshifumi
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (11) : 1189 - 1191
  • [33] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Mbakam, Cedric Happi
    Lamothe, Gabriel
    Tremblay, Guillaume
    Tremblay, Jacques P.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 931 - 941
  • [34] CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
    Cedric Happi Mbakam
    Gabriel Lamothe
    Guillaume Tremblay
    Jacques P. Tremblay
    Neurotherapeutics, 2022, 19 : 931 - 941
  • [35] Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy
    Cope, Heidi
    Fischer, Ryan
    Heslop, Emma
    McNiff, Megan
    Johnson, Alexandra
    Camino, Eric
    Denger, Brian
    Armstrong, Niki
    Thakrar, Sejal
    Bateman-House, Alison
    Beaverson, Katherine L.
    Woollacott, Ione O. C.
    Phillips, Dawn
    Fernandez, Vivian
    Ganot, Annie
    Donisa-Dreghici, Roxana
    Mansfield, Carol
    Peay, Holly
    JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (05) : 1085 - 1093
  • [36] Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond
    Duan, Dongsheng
    HUMAN GENE THERAPY, 2023, 34 (9-10) : 345 - 349
  • [37] Duchenne muscular dystrophy, one of the most complicated diseases for gene therapy
    Braun, Serge
    JOURNAL OF TRANSLATIONAL GENETICS AND GENOMICS, 2025, 9 (01) : 35 - 47
  • [38] Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy
    Ferrer, A
    Wells, KE
    Wells, DJ
    GENE THERAPY, 2000, 7 (17) : 1439 - 1446
  • [39] A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
    Botti, Valeria
    Menzel, Olivier
    Staedler, Davide
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Use of the dog model for Duchenne muscular dystrophy in gene therapy trials
    Howell, JM
    Fletcher, S
    Kakulas, BA
    OHara, M
    Lochmuller, H
    Karpati, G
    NEUROMUSCULAR DISORDERS, 1997, 7 (05) : 325 - 328